All Updates

All Updates

icon
Filter
M&A
Otsuka Pharmaceutical acquires Jnana Therapeutics for USD 800 million to advance its drug discovery platform and ongoing pipeline
Precision Medicine
Aug 1, 2024
This week:
Partnerships
T-Mobile partners with OpenAI to develop AI-powered customer service platform
Generative AI Applications
Today
Partnerships
Runway partners with Lionsgate to develop AI video tools using studio's movie catalog
Generative AI Applications
Yesterday
Funding
QMill raises EUR 4 million in seed funding to provide quantum computing industrial applications
Quantum Computing
Yesterday
Product updates
QuiX Quantum launches 'Bia' quantum cloud computing service for quantum solutions
Quantum Computing
Yesterday
Partnerships
Oxford Ionics and Infineon Technologies partner to build portable quantum computer for Cyberagentur
Quantum Computing
Yesterday
Partnerships
Product updates
Tencent Ai Lab launches EzAudio AI for text-to-audio generation with Johns Hopkins University
Foundation Models
Yesterday
Funding
TON secures USD 30 million in investment from Bitget and Foresight Ventures
Web3 Ecosystem
Yesterday
Funding
Hemi Labs raises USD 15 million in funding to launch blockchain network
Web3 Ecosystem
Yesterday
Product updates
Fivetran launches Hybrid Deployment for data pipeline management
Machine Learning Infrastructure
Yesterday
Product updates
Fivetran launches Hybrid Deployment for data pipeline management
Data Infrastructure & Analytics
Yesterday
Precision Medicine

Precision Medicine

Aug 1, 2024

Otsuka Pharmaceutical acquires Jnana Therapeutics for USD 800 million to advance its drug discovery platform and ongoing pipeline

M&A

  • Otsuka Pharmaceutical has entered a definitive merger agreement to fully acquire Jnana Therapeutics for USD 800 million with an additional payment of up to USD 325 million dependent on development and regulatory milestones. The acquisition is expected to close in Q3 2024.

  • The acquisition will be executed by merging a special purpose company, created under Otsuka America (OAI) for this purpose, into Jnana Therapeutics, with Jnana remaining as the surviving entity.

  • Following the acquisition, Otsuka aims to enhance its R&D, leveraging Jnana’s next-generation RAPID platform, and expand its global influence. The firm aims to address unmet needs in PKU and autoimmune diseases using Jnana’s technology and small molecule pipeline, which will be added to Otsuka's existing portfolio in the specialty/autoimmune diseases segment.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.